In summary, we have shown here that the oncolytic CVB3 PD-H synergistically enhances the cytotoxic activity of the drugs of the FOLFOXIRI regimen in the CRC cell line Colo320. The gene discussed is PDP1; the disease is colorectal carcinoma.